193 related articles for article (PubMed ID: 35913674)
1. Regulatory Agencies and PET/CT Imaging in the Clinic.
Herscovitch P
Curr Cardiol Rep; 2022 Oct; 24(10):1361-1371. PubMed ID: 35913674
[TBL] [Abstract][Full Text] [Related]
2. Federal regulations and reimbursement for PET.
Keppler JS
J Nucl Med Technol; 2001 Dec; 29(4):173-9; quiz 180-2. PubMed ID: 11756528
[TBL] [Abstract][Full Text] [Related]
3. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
Barrio JR; Marcus CS; Hung JC; Keppler JS
Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
[TBL] [Abstract][Full Text] [Related]
4. Medicare coverage of PET for cervical cancer.
Carey BP; Coleman RE; Grigsby PW; Siegel BA
J Am Coll Radiol; 2006 Jan; 3(1):19-22. PubMed ID: 17412001
[TBL] [Abstract][Full Text] [Related]
5. New pathways to medicare coverage for innovative PET radiopharmaceuticals: report of a medical imaging & technology alliance (MITA) workshop.
Hillman BJ; Frank RA; Rodriguez GM;
J Nucl Med; 2012 Feb; 53(2):336-42. PubMed ID: 22178626
[TBL] [Abstract][Full Text] [Related]
6. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for Medicare coverage of new PET radiopharmaceuticals.
Hillman BJ; Frank RA; Abraham BC
J Nucl Med; 2013 Sep; 54(9):1675-9. PubMed ID: 23907756
[TBL] [Abstract][Full Text] [Related]
7. New pathways to medicare coverage for innovative PET radiopharmaceuticals: report of a Medical Imaging & Technology Alliance (MITA) workshop.
Hillman BJ; Frank RA; Rodriguez GM;
J Am Coll Radiol; 2012 Feb; 9(2):108-14. PubMed ID: 22192574
[TBL] [Abstract][Full Text] [Related]
8. Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program.
Moneer O; Rathi VK; Johnston JL; Ross JS; Dhruva SS
JAMA Cardiol; 2023 Dec; 8(12):1174-1181. PubMed ID: 37878306
[TBL] [Abstract][Full Text] [Related]
9. The future of positron emission tomography in clinical medicine and the impact of drug regulation.
Coleman RE; Robbins MS; Siegel BA
Semin Nucl Med; 1992 Jul; 22(3):193-201. PubMed ID: 1523417
[TBL] [Abstract][Full Text] [Related]
10. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
Lindsay MJ; Siegel BA; Tunis SR; Hillner BE; Shields AF; Carey BP; Coleman RE
AJR Am J Roentgenol; 2007 Apr; 188(4):1109-13. PubMed ID: 17377055
[TBL] [Abstract][Full Text] [Related]
11. Clinical PET scanning. A "short-lived" orphan.
Coleman RE; Briner WH; Siegel BA
Int J Technol Assess Health Care; 1992; 8(4):610-22. PubMed ID: 1464482
[TBL] [Abstract][Full Text] [Related]
12. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
13. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
Hyland CJ; Varghese F; Yau C; Beckwith H; Khoury K; Varnado W; Hirst GL; Flavell RR; Chien AJ; Yee D; Isaacs CJ; Forero-Torres A; Esserman LJ; Melisko ME
J Natl Compr Canc Netw; 2020 Nov; 18(11):1510-1517. PubMed ID: 33152704
[TBL] [Abstract][Full Text] [Related]
14. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for medicare coverage of new PET radiopharmaceuticals.
Hillman BJ; Frank RA; Abraham BC
J Am Coll Radiol; 2013 Sep; 10(9):689-94. PubMed ID: 23916799
[TBL] [Abstract][Full Text] [Related]
15. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
16. Authority of Medicare to Limit Coverage of FDA-Approved Products: Legal and Policy Considerations.
Daval CJR; Kesselheim AS
JAMA Intern Med; 2023 Sep; 183(9):999-1004. PubMed ID: 37505487
[TBL] [Abstract][Full Text] [Related]
17. Resected colorectal cancer among Medicare beneficiaries:adoption of FDG PET.
Zafar HM; Mahmoud NN; Mitra N; Wirtalla C; Armstrong K; Groeneveld PW
Radiology; 2010 Feb; 254(2):501-8. PubMed ID: 20093522
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Technical Considerations for Brain PET Imaging for Dementia.
Acuff SN; Mathotaarachchi S; Zukotynski K; Osborne D; Subramaniam R;
J Nucl Med Technol; 2020 Mar; 48(1):5-8. PubMed ID: 31182663
[TBL] [Abstract][Full Text] [Related]
19. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
20. Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations.
Bunning S; Ignace C; Mattmuller S; Schwarz SW; Scott PJH; VanBrocklin HF; Zigler SS;
J Nucl Med; 2022 Jul; 63(7):1117-1123. PubMed ID: 35058318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
